Abstracts Archive - Page 661 of 2425 - ACR Meeting Abstracts

Abstract Number: 0493 • ACR Convergence 2020
Automatic Joint Space Assessment in Hand Radiographs with Deep Learning Among Patients with Rheumatoid Arthritis
Yun-Ju Huang¹, Chang-Fu Kuo¹, Fakai Wang², Shun Miao², Kang Zheng² and Le Lu², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), ²PAII labs, Bethesda, MD
Background/Purpose: Assessment of joint space is the fundamental radiographic task to diagnose rheumatoid arthritis (RA) and to assess the severity and progression of the disease.…
Abstract Number: 0488 • ACR Convergence 2020
Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database
Sebastian Sattui¹, Iris Navarro-Millan², Fenglong Xie³, Mangala Rajan², Huifeng Yun⁴ and Jeffrey R Curtis⁴, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: There is growing interest regarding the role of neuroinflammation in the development of dementia and the potential role for anti-inflammatory therapy, including TNF-inhibitors (TNFi),…
Abstract Number: 0502 • ACR Convergence 2020
Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis
Sara Rahmati¹, Fatima Abji¹, Proton Rahman² and Vinod Chandran³, ¹University Health Network, Toronto, ON, Canada, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better…
Abstract Number: 0501 • ACR Convergence 2020
Structural Entheseal Lesions in Psoriasis Patients Are Associated with an Increased Risk Ofprogression to Psoriatic Arthritis – A Prospective Cohort Study
David Simon¹, Koray Tascilar¹, Arnd Kleyer¹, Sara Bayat², Eleni Kampylafka², Axel Hueber³, Juergen Rech¹, Louis Schuster¹, Klaus Engel⁴, Michael Sticherling² and Georg Schett⁵, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, ⁴Siemens Healthcare GmbH Digital Technology & Camp; Innovation, SHS DS DTI, Erlangen, Germany, ⁵Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: We have previously reported that the presence of musculoskeletal pain in psoriasis patients is associated with a higher risk of developing psoriatic arthritis (PsA)…
Abstract Number: 0507 • ACR Convergence 2020
Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study
Grace Wright¹, Peter Nash², Laura Coates³, Jordi Gratacós⁴, Frank Behrens⁵, Kevin Ding⁶, Weibin Bao⁷, Luminita Pricop⁶, Corine Gaillez⁸ and Iain McInnes⁹, ¹Association of Women in Rheumatology, New York, NY, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Oxford, Oxford, United Kingdom, ⁴University Hospital Parc Tauli Sabadell, Barcelona, Spain, ⁵CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁶Novartis Pharmaceuticals Corporation, East Hanover, ⁷Novartis Pharmaceuticals Corporation, East Hannover, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Lower efficacy to anti-tumor necrosis factor treatment has been reported in female patients with psoriatic arthritis (PsA) as compared to males in clinical registries.1…
Abstract Number: 0506 • ACR Convergence 2020
Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Iain McInnes¹, Proton Rahman², Alice Gottlieb³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Xie Xu⁶, Ramanand Subramanian⁷, Prasheen Agarwal⁷, Shihong Sheng⁷, Yusang Jiang⁷, Bei Zhou⁷, Désirée van der Heijde⁸ and Philip Mease⁹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Research & Development, LLC, San Marcos, CA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis. Through Week24 (W24) of the Ph3,…
Abstract Number: 0512 • ACR Convergence 2020
Efficacy of Apremilast for the Treatment of Manifestations of Behçet’s Syndrome Other Than Oral Ulcers, Including Skin Lesions and Arthritis
Gülen Hatemi¹, Alfred Mahr², Mitsuhiro Takeno³, Doyoung Kim⁴, Melike Melikoğlu¹, Sue Cheng⁵, Sven Richter⁵, Michele Brunori⁶, Maria Paris⁵, Mindy Chen⁵ and Yusuf Yazici⁷, ¹Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, ²Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ³Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, ⁵Amgen Inc., Thousand Oaks, ⁶Amgen Europe GmbH, Rotkreuz, Switzerland, ⁷New York University School of Medicine, New York
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful and recurrent oral ulcers (OU) and other manifestations, such as skin lesions and…
Abstract Number: 0514 • ACR Convergence 2020
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2). In these trials, response to…
Abstract Number: 0509 • ACR Convergence 2020
Classification of Patients with Relapsing Polychondritis Based on Somatic Mutations in UBA1
Marcela Ferrada¹, Keith Sikora², Sinisa Savic³, Yiming Luo⁴, Kristina Wells⁵, Emily Rose¹, Kaitlin Quinn⁶, Wendy Goodspeed¹, Anne Jones⁷, Mimi Le⁸, Amanda Ombrello⁹, Zuoming Deng¹⁰, Massimo Gadina¹¹, Wanxia Tsai¹², Ivona Aksentijevich⁷, Daniel Kastner¹³, David Beck¹⁴ and Peter C. Grayson¹⁵, ¹Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institutes of Health Clinical Center, Bethesda, MD, ³University of Leeds, England, United Kingdom, ⁴Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ⁵Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ⁶Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ⁷National Human Genome Research Institute, Bethesda, MD, ⁸Oregon Health & Science University, Portland, ⁹National Institutes of Health, Bethesda, ¹⁰National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, ¹¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ¹²National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, MD, ¹³National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ¹⁴National Human Genome Research Institute, Bethesda, ¹⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare, heterogenous, systemic inflammatory disease with a predilection for cartilaginous structures. Recently we discovered myeloid-restricted somatic mutations in UBA1 in…
Abstract Number: 0504 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Mark Genovese¹, Apinya Lertratanakul², Jaclyn K Anderson², Kim Papp³, William Tillett⁴, Filip Van den Bosch⁵, Shigeyoshi Tsuji⁶, Eva Dokoupilova⁷, Mauro Keiserman⁸, Xin Wang², Sheng Zhong², Patrick Zueger², Aileen Pangan⁹ and Philip Mease¹⁰, ¹Stanford University Medical Center, Palo Alto, CA, ²AbbVie Inc., North Chicago, IL, ³Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, ⁷Uherske Hradiste and University of Veterinary and Pharmaceutical Sciences,, Brno, Czech Republic, ⁸Pontificial Catholic University, Porto Alegre, Brazil, ⁹Abbvie Inc., La Grange, IL, ¹⁰Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment…
Abstract Number: 0517 • ACR Convergence 2020
Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study
Thomas Garvey¹, Cynthia Crowson², Matthew J. Koster³ and Kenneth Warrington³, ¹Mayo Clinic Rochester, Apple Valley, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Diagnostic methods for giant cell arteritis (GCA) have evolved over recent decades, and large vessel imaging plays an increasing role in disease detection. The…
Abstract Number: 0520 • ACR Convergence 2020
Antiphospholipid Antibodies and Thrombotic Events in COVID-19 Patients Hospitalized in Medicine Ward
Alexandre Le Joncour¹, Corinne Frere¹, Isabelle Martin-Toutain¹, Paul Gougis¹, Pascale Ghillani-Dalbin¹, Georgina Maalouf¹, Matheus Vieira¹, Anne-Genevieve Marcelin¹, Joe-Elie Salem¹, Yves Allenbach², David Saadoun³, Olivier Benveniste⁴ and Patrice Cacoub¹, ¹APHP, paris, France, ²Sorbonne Université, Paris, Ile-de-France, France, ³AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, PAris, France, ⁴Sorbonne Université, paris, France
Background/Purpose: A high prevalence of thrombotic events has been reported in critically ill COVID-19 patients but data on the prevalence of thrombosis in ward patients…
Abstract Number: 0521 • ACR Convergence 2020
Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?
Flavio Signorelli¹, Gustavo Balbi², Eloisa Bonfa³, Eduardo Borba⁴ and Danieli Andrade⁵, ¹Universidade de São Paulo, Rio de janeiro, Rio de Janeiro, Brazil, ²Universidade de São Paulo, Juiz de Fora, Minas Gerais, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…
Abstract Number: 0516 • ACR Convergence 2020
Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial
Sebastian Unizony¹, Shalini V. Mohan², Jian Han² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: To investigate the characteristics of disease flare after successful treatment with tocilizumab (TCZ) in patients with giant cell arteritis (GCA).Methods: We performed a post…
Abstract Number: 0524 • ACR Convergence 2020
Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases
Yann Nguyen¹, Cécile Yelnik², Nathalie Morel³, Romain Paule⁴, Pierre-Yves Hatron², Romain Stammler⁵, Léo Plaçais³, Jean-Charles Piette⁶, Luc Mouthon⁷, Eric Hachulla⁸, Marc Lambert², Le Guern Véronique³ and Nathalie Costedoat-Chalumeau⁹, ¹1Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, ²Department of Internal Medicine and Clinical Immunology, National Referral Centre for rare Systemic Auto-immune Diseases North and North-West of France (CeRAINO), CHU Lille, Hôpital Claude Huriez, Lille, France, Lille, France, ³National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, France, ⁴Department of Internal Medicine, Hôpital Foch, Suresnes, France, Suresnes, France, ⁵National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, ⁶Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁸Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, ⁹APHP, Université de Paris, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) is a heterogeneous disease, with different phenotypes which may widely vary from classical thrombotic or obstetrical manifestations to catastrophic antiphospholipid syndrome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].